I am a:
Menu

Defend with Profend® Nasal Decolonization Kit

Be The Difference with PDI

February 28, 2022

No single approach can fully eliminate the risk of healthcare-associated infections (HAIs). That’s why healthcare institutions need multiple layers of defense to attack infections from all angles. Profend® nasal decolonization kit can help provide effective infection risk reduction at the innermost layer: patients themselves. It’s just one of PDI Healthcare’s integrated products that helps you implement an overall infection prevention strategy.

Patients need surgical site infection (SSI) risk reduction:

  • 30% of healthy adults have S. aureus in their nasal passages1
  • 85% of S. aureus SSIs come from the patient’s own nasal flora2
  • Nasal colonization increases the risk of getting an SSI up to 9 times, 3 and each SSI costs up to $60,0004

Nasal decolonization with PVP-Iodine is now a CDC core strategy for reducing S. aureus in high-risk surgeries.5

Why use Profend® PVP-Iodine Nasal Decolonization Swabs?

  • Apply in nose for just 60 seconds—15 seconds x 4 swabs = one application
  • Up to 2.5x faster application than other PVP-Iodine swabs6
  • Pre-saturated swabs need no preparation—just snap and swab
  • Slim, compact design for patient comfort
  • Clinician-administered for 100% compliance
  • Preferred by over 90% of clinicians surveyed for speed and efficiency compared to other PVP-Iodine swabs7
  • 96.6% of patients surveyed are comfortable with nasal application of PVP-Iodine8

Did You Know?

  • The nose is the primary reservoir for the leading SSI pathogen, S. aureus (Staphylococcus aureus)?
  • PDI’s Profend® Nasal Decolonization Kit can kill 99.7% of S. aureus in just 10 mins?9
  • The Profend® Nasal Decolonization kit is not only suitable for use in the OR with MRSA and S. aureus-colonized patients, but also in ICU patients?10
  • PDI’s Profend® Nasal Decolonization kit aligns with AORN and CDC guidelines for skin antisepsis and pre-op treatment?11
  • An SSI on average costs $21,000? 12
  • 10% PVP-I, as a broad-spectrum antiseptic for nasal decolonization, shows no evidence of bacterial resistance aligning with healthcare goals of decreasing drug resistant opportunities?13

Learn more at www.DefendwithProfend.com

References:

1. VandenBergh MF, Yzerman EP, van Belkum A, Boelens HA, Sijmons M, Verbrugh HA. Follow-up of Staphylococcus aureus nasal carriage after 8 years: redefining the persistent carrier state. J Clin Microbiol. 1999;37:3133–3140. 2. Septimus EJ. Nasal Decolonization: What antimicrobials are more effective prior to surgery? Am J Infect Control 2019;47S:A53-A57. doi: 10.1016/j.ajic.2019.02.028. 3. Kalmeijer MD, van Nieuwland-Bollen E, Bogaers-Hofman D, de Baere GA. Nasal carriage of Staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic surgery. Infect Control Hosp Epidemiol. 2000;21(15)319-323. 4. Anderson DJ, Kaye KS, Chen LF, Schmader KE, Choi Y, et al. Clinical and Financial Outcomes Due to Methicillin Resistant Staphylococcus Aureus Surgical Site Infection: A Multi-Center Matched Outcomes Study. PLOS ONE. 2009;4(12):e8305. doi:10.1371/journal.pone.0008305. 5. Centers for Disease Control and Prevention. Strategies to Prevent Hospital-onset Staphylococcus aureus Bloodstream Infections in Acute Care Facilities. https://www.cdc.gov/hai/prevent/staph-prevention-strategies.html. Published December 2019. Accessed December 10, 2020. 7. Instructions for use. 8. PDI user acceptance study. 9. Maslow J, Hutzler L, Cuff G, Rosenberg A, Phillips M, Bosco J. Patient experience with mupirocin or povidone-iodine nasal decolonization. Orthopedics. 2014;37(6):e576–e581. 9. 1PDI in vivo Study 0113-CTEVO. 10. Citation: Sievert D. Antimicrobial-resistant pathogens associated with healthcare associated infections: summary of data reported to the NHSN at the CDC, 2009-2010. Infect Control Hosp Epidemiol. 2013;34(1):1–14. 11. Citation: https://www.cdc.gov/hai/data/portal/index.html 12. Citation: https://jamanetwork.com/journals/jama/article-abstract/2752664 13. PDI Study PDI-0113-KT1

*Surgical site infections

Related Information